Breakthrough Science to Next-Generation Therapies

rngen is an innovative virtual pharmaceutical company () developing first-in-class therapies targeting both orphan and multi-billion-dollar markets with limited or no effective treatments. Our approach leverages a capital-efficient model, allowing us to advance breakthrough treatments while minimizing costs and maximizing investor returns. Our lead drug candidate, KYC, has demonstrated strong preclinical efficacy, positioning us for substantial growth in pulmonary neurology, and hematology, and medicine.

Why Invest in rngen

Significant Market Opportunity

rngen is addressing a spectrum of diseases with substantial unmet medical needs. For instance, the global market for Neonatal and Acute Respiratory Distress Syndrome (NRDS and ARDS) is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.56% from 2024 to 2034, driven by advancements in surfactant therapies and non-invasive ventilation techniques. Sickle Cell Disease (SCD) affects approximately 7.74 million people globally as of 2021, with a 41.4% increase since 2000, primarily due to population growth in regions like sub-Saharan Africa and India. Traumatic Brain Injury (TBI) had 27.16 million new cases worldwide in 2019, highlighting the vast need for effective interventions. Despite the prevalence and severity of these conditions, current treatment options remain limited or non-existent, underscoring the critical need for innovative rngen therapies.

Expanding Market Opportunity

By addressing both rare diseases with high medical urgency and larger markets with substantial commercial potential, rngen offers multiple avenues for growth and revenue generation.

Multi-Indication Potential

Our lead compound and compound library possess broad therapeutic applications across diversified market opportunities and provide risk mitigation.

Proven Leadership & Model

rngen operates as a next generation , leveraging a highly specialized global network of scientific, clinical, and business leaders. Our executive team has a proven track record in drug development, regulatory strategy, and commercialization, with multiple successful biotech exits and licensing deals. The model enables capital-efficient R&D, reducing overhead and accelerating progress towards high-value milestones, including FDA and CPA IND submissions and Phase I trials.

First-in-Class Drug Development

KYC and our library of systems chemico-pharmacology drugs (SCPD) operate through a unique mechanism of action, distinct from existing therapies. They have demonstrated strong preclinical pharmacodynamic properties, offering potential disease-modifying effects.

Strong Preclinical Data & De-Risked Pipeline

KYC has shown compelling safety and efficacy in multiple validated animal models. Our non-dilutive NIH SBIR funding model has supported rigorous preclinical validation, significantly reducing early-stage investment risk.

Regulatory & Clinical Pathway

We are actively preparing for IND filings in BPD, NRDS, and SCD in 2026, with Phase I clinical trials for SCD expected in 2027. Our stepwise regulatory strategy ensures each milestone builds investor value, with upcoming preclinical toxicology data in 2025, IND-enabling studies in 2026, and targeted FDA/CPA submissions by 2027. These milestones de-risk development and position rngen for high-value licensing discussions with major pharma partners.

Exit Strategy & Potential ROI

rngen is actively engaging with strategic pharmaceutical partners in neurology, hematology, and pulmonology, targeting licensing deals and potential acquisition post-Phase II trials. Our focus aligns with industry leaders such as Pfizer, Lilly, AbbVie, GSK, BMS, Biogen, Novartis, and Vertex, who have demonstrated strong interest in next-generation treatments for these high-burden diseases.

Investment Pathways

We are seeking strategic partners and investors to support our clinical and commercial roadmap. Opportunities include:

  • Venture Capital & Private Equity – Growth-stage funding for clinical trials and regulatory approval.
  • Angel Investors – Early-stage investment from those passionate about advancing medical innovation.
  • Family Offices – Long-term capital aligned with meaningful healthcare impact.

Funding & Use of Proceeds

ReNeuroGen is currently raising $12.5 million in Series A funding to support:

  • IND-enabling studies and regulatory submission
  • Phase I clinical trial initiation
  • Manufacturing scale-up and CMC (Chemistry, Manufacturing, and Controls) development
  • Business development and partnership engagement

Risk Mitigation & Competitive Advantage

Rngen’s strategy mitigates early-stage development risks through:

  • Extensive NIH SBIR grant funding, reducing capital burn while validating our scientific approach
  • A that optimizes efficiency and minimizes operational overhead
  • A highly experienced management and scientific advisory team with expertise in drug development, regulatory strategy, and commercialization

Next Steps for Investors

To explore this investment opportunity and receive our Investor Deck, please contact: Stephen Naylor PhD – CEO, ReNeuroGen LLC

We welcome discussions with angel investors, venture capital firms, and strategic partners interested in transforming the treatment landscape for SCD, BPD, NRDS and ARDS.